Therapeutic blockade of IL‐17, whilst beneficial in MS,62 arthritis63 and psoriasis,64 does not improve AD68 and was shown to result in exacerbation of existing65, 66 and even de novo67 IBD pathology, as well as increased incidence of Candida infections.29 Here, IL17A is linked to inflammatory bowel disease.